10-Q: THC Therapeutics Reports Q1 2024 Results: Minimal Revenue, Reduced Operating Loss, and Ongoing Going Concern Concerns

THC Therapeutics reports no revenue for Q1 2024, but manages to decrease its operating loss compared to the same period last year, while still facing substantial doubt about its ability to continue as a going concern.

Summary

• THC Therapeutics, Inc. filed its Form 10-Q for the quarter ended October 31, 2023.
• The company reported no revenue for the three months ended October 31, 2023, and October 31, 2022.
• The operating loss decreased to $55,218 for the three months ended October 31, 2023, compared to $107,562 for the same period in 2022.
• Net loss for the quarter was $62,485, a significant decrease from the $2,134,302 net loss in the same period last year.
• As of October 31, 2023, the company had cash of $10.
• The company's accumulated deficit as of October 31, 2023, was $38,486,430.
• The report indicates substantial doubt about the company's ability to continue as a going concern, dependent on generating revenues and raising capital.
• Subsequent to the quarter, on January 31, 2024, the Company and Iliad entered into a Settlement Agreement and Mutual Release to fully settle all disputes related to the Case and the Arbitration.
• On November 17, 2023, the Company sold 56 shares of Series C Preferred Stock for $48,920, net of $5,080 in offering cost.
• On March 13, 2024, the Company sold 56 shares of Series C Preferred Stock for $48,920, net of $5,080 in offering cost.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the lack of revenue, significant accumulated deficit, and substantial doubt about the company's ability to continue as a going concern. While the operating loss decreased, the overall financial situation remains precarious.

Positives

• The operating loss decreased significantly compared to the same period last year, indicating improved cost management.
• The net loss decreased substantially compared to the same period last year.
• The company settled disputes with Iliad Research and Trading, L.P.
• The company continues to develop its dHydronator product, which has potential in the cannabis and home herb and garden product markets.

Negatives

• The company reported no revenue for the three months ended October 31, 2023.
• The company has a significant accumulated deficit of $38,486,430.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has minimal cash reserves, with only $10 on hand as of October 31, 2023.
• The company's disclosure controls and procedures were not effective.

Risks

• The company's ability to continue as a going concern is dependent on generating revenues and raising capital.
• The company faces competition from other commercial herb dryers.
• The company's success depends on the market acceptance of its dHydronator product.
• The company's financial condition is weak, with a significant accumulated deficit and minimal cash reserves.
• The company's disclosure controls and procedures were not effective, which could lead to inaccurate financial reporting.

Future Outlook

The company plans to use borrowings and security sales to mitigate the effects of cash flow deficits, but there is no assurance that debt or equity financing will be available.

Management Comments

• Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the consolidated financial statements are issued and determined that substantial doubt exists about the Company's ability to continue as a going concern.
• Such discussion represents only the best present assessment from our Management.

Industry Context

The company operates in the wellness industry, specifically targeting the cannabis and home herb and garden product markets with its dHydronator product.

Comparison to Industry Standards

• The report mentions Yofumo Technologies as a competitor with commercially available herb dryers and significant market share.
• The company claims its dHydronator can dry cannabis in less than 14 hours, compared to traditional methods that take up to 14 days.
• The company's proprietary sanitizing technology brought the failing TAC (total aerobic count) from over 300,000 CFU/g down to 78,000 CFU/g (anything less than 100,000 CFU/g is considered passing) in the second test.

Legal Proceedings

• The company was involved in a legal dispute with Iliad Research and Trading, L.P., which has been settled on January 31, 2024.

Related Party Transactions

• Advances from related parties consist of $59,917 from B. Romanek, President and CEO as of October 31, 2023.
• Convertible notes payable related party with a balance of $130,761 as of October 31, 2023.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees' job security is uncertain due to the company's financial challenges.
• Customers are impacted by the uncertainty surrounding the company's ability to deliver its dHydronator product.

Next Steps

• The company plans to source parts for serial manufacturing of the dHydronator.
• The company plans to negotiate and secure serial manufacturing and assembly.
• The company plans to hire sales and marketing staff as funds are available.
• The company intends to engage in further development efforts once it has at least $2,000,000 in available cash flow or funds from other operations and if it receives the patent.
• The parties are in the process of identifying new 2024 trial dates for the Iliad dispute.

Key Dates

Keywords

dHydronator, herb dryer, cannabis, financial results, going concern, THC Therapeutics, operating loss, net loss, revenue, preferred stock